NLS Pharmaceutics Ltd.
13F holders, Q2 2025 (June 30)3holders +1
1new positions
0sold out
$2.90avg. 13F price*
At the end of Q2 2025, 3 institutions reported holding NLS Pharmaceutics Ltd. in their 13F filings, up 1 from Q1 2025. 1 opened new positions and 0 sold out. The largest holders were BVF Inc. ($417K), UBS Group AG ($43K) and Morgan Stanley ($7K).
- Company
- NLS Pharmaceutics Ltd.
- CUSIP
- H57830137
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $7K |
| Exits | 0 | $0 |
All 13F filers, Q1 2025 → Q2 2025: 2,510 shares bought and 10,755 shares sold, net −8,245 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| BVF Inc. | 0.01% | No change | 143,676 | $417K |
| UBS Group AG | 0.00% | Reduce -41.8% | 14,982 | $43K |
| Morgan Stanley | 0.00% | New | 2,510 | $7K |
"% of holder's portfolio" is NLS PHARMACEUTICS LTD's weight in each manager's 13F, not the share of NLS Pharmaceutics Ltd. the manager owns.